Sorrento Therapeutics (SRNE) Stock Price, News & Analysis

Company Overview

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a clinical-stage biopharmaceutical company focused on developing therapies for oncology, autoimmune disorders, and inflammatory pain. Founded in 2006 and headquartered in San Diego, California, the firm leverages proprietary platforms to create targeted treatments that harness the power of antibodies, cell therapies, and small molecules. Its diversified pipeline includes antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and immunomodulators designed to address unmet medical needs.

The company’s lead programs span multiple stages of clinical development. Sorrento’s ADC platform aims to deliver potent cytotoxic agents directly to tumor cells while minimizing systemic exposure, and its CAR-T portfolio targets hematological malignancies with next-generation constructs engineered for enhanced safety and efficacy. In addition to oncology, the company is advancing non-opioid pain management therapies, including cannabinoid-based formulations and small molecules that modulate inflammatory pathways.

Sorrento has expanded its global footprint through strategic collaborations, research partnerships, and acquisitions. The company maintains research laboratories and manufacturing sites in the United States and China, enabling cross-border development and regulatory initiatives. Collaborative agreements with academic institutions and biopharmaceutical partners support translational research and aim to accelerate the progression of its lead assets toward approval.

Under the leadership of founder and Chief Executive Officer Henry Ji, Ph.D., Sorrento’s executive team brings together seasoned experts in drug discovery, clinical operations, regulatory affairs, and commercial strategy. The board of directors features industry veterans who have overseen pivotal clinical trials and successful product launches. Looking ahead, the company plans to advance its clinical pipeline, deepen strategic alliances, and ultimately deliver novel therapies to patients worldwide.

Key Stats

• Today's Range: $0.0013 to $0.0024
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: 78,192 shs
• Average Volume: 92,222 shs
• Market Capitalization: $1.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Sorrento Therapeutics Stock Analysis - MarketRank™

Sorrento Therapeutics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sorrento Therapeutics.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.67% of the float of Sorrento Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sorrento Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Sorrento Therapeutics has recently increased by 2.62%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sorrento Therapeutics does not currently pay a dividend.

Dividend Growth

Sorrento Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.46

Percentage of Shares Shorted

0.67% of the float of Sorrento Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sorrento Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Sorrento Therapeutics has recently increased by 2.62%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for SRNE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Sorrento Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sorrento Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.60% of the stock of Sorrento Therapeutics is held by insiders.

Percentage Held by Institutions

Only 0.02% of the stock of Sorrento Therapeutics is held by institutions.

SRNE Stock Analysis - Frequently Asked Questions

How have SRNE shares performed this year?

Sorrento Therapeutics' stock was trading at $0.0005 at the beginning of 2025. Since then, SRNE stock has increased by 380.0% and is now trading at $0.0024.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sorrento Therapeutics investors own include NIO (NIO), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ).

Company Calendar

• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRNE
• CIK: 850261
• Web: www.sorrentotherapeutics.com
• Phone: (858) 203-4100
• Fax: 858-210-3759
• Employees: 800
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $60.32 million
• Price / Sales: 0.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 551,280,000
• Free Float: 536,948,000
• Market Cap: $1.32 million
• Optionable: No Data
• Beta: 0.98